Source: Annual Congress 2012 - MDR- and XDR-TB: clinical and public health experiences
Disease area: Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
K.W. Jo, W. Ji, J. Lyu, Y.J. Jung, S.D. Lee, W.S. Kim, D.S. Kim, T.S. Shim (Seoul, Republic Of Korea). The efficacy of a rifabutin-containing regimen for rifabutin-susceptible multidrug-resistant tuberculosis. Eur Respir J 2012; 40: Suppl. 56, 3319

Member's Comments

No comment yet.

Related content which might interest you: Bedaquiline-based treatment regimen for multidrug-resistant tuberculosis Source: Eur Respir J, 49 (5) 1700742; 10.1183/13993003.00742-2017 Year: 2017 The individual-tailored treatment regimens for multidrug-resistant tuberculosis Source: Annual Congress 2012 - MDR- and XDR-TB: clinical and public health experiences Year: 2012 Evaluation of co-trimoxazole in the treatment of multidrug-resistant tuberculosis Source: Eur Respir J 2013; 42: 504-512 Year: 2013 Efficacy and tolerability of linezolid in multidrug-resistant tuberculosis (MDR/XDR-TB) Source: Annual Congress 2008 - The challenge of multidrug-resistant tuberculosis Year: 2008 Linezolid in multidrug-resistant tuberculosis treatment Source: Eur Respir J 2004; 24: Suppl. 48, 485s Year: 2004 Is bedaquiline as effective as fluoroquinolones in the treatment of multidrug-resistant tuberculosis? Source: Eur Respir J 2016; 48: 582-585 Year: 2016 Compassionate use of delamanid in combination with bedaquiline for the treatment of multidrug-resistant tuberculosis Source: Eur Respir J, 53 (1) 1801154; 10.1183/13993003.01154-2018 Year: 2019 Ertapenem in the treatment of multidrug-resistant tuberculosis: first clinical experience Source: Eur Respir J 2016; 47: 333-336 Year: 2016 A study on the clinical efficacy of a combination regimen with azithromycin and capreomycin in the treatment of multi-drug resistant pulmonary tuberculosis Source: Eur Respir J 2004; 24: Suppl. 48, 722s Year: 2004 Clarithromycin increases linezolid exposure in multidrug-resistant tuberculosis patients Source: Eur Respir J 2013; 42: 1614-1621 Year: 2013 Safety and tolerability of clarithromycin in the treatment of multidrug-resistant tuberculosis Source: Eur Respir J , 49 (3) 1601612; DOI: 10.1183/13993003.01612-2016 Year: 2017 Linezolid: an effective, safe and cheap drug for patients failing multidrug-resistant tuberculosis treatment in India Source: Eur Respir J 2012; 39: 956-962 Year: 2012 Resistance to second-line injectables and treatment outcomes in multidrug-resistant and extensively drug-resistant tuberculosis cases Source: Eur Respir J 2008; 31: 1155-1159 Year: 2008 Efficacy and safety of linezolid for the treatment of multidrug resistant tuberculosis (MDR-TB) and disease by non tuberculous mycobacteria (NTM) Source: Annual Congress 2011 - Treatment of tuberculosis and adverse drug reactions Year: 2011 Clinical efficacy and safety of clarithromycin in the treatment of multi-drug resistant tuberculosis Source: Annual Congress 2009 - Treatment of tuberculosis at times of emerging drug resistance Year: 2009 A regimen containing bedaquiline and delamanid compared to bedaquiline in patients with drug-resistant tuberculosis Source: Eur Respir J, 55 (1) 1901181; 10.1183/13993003.01181-2019 Year: 2020 Efficacy of empiric chemotherapy regimen in patients with multidrug resistant (MDR) tuberculosis Source: Eur Respir J 2004; 24: Suppl. 48, 656s Year: 2004 What is the optimal dosage of linezolid in treatment of complicated multidrug-resistant tuberculosis? Source: Eur Respir J 2009; 34: 1492-1494 Year: 2009 Pharmacokinetics of ertapenem in patients with multidrug-resistant tuberculosis Source: Eur Respir J 2016; 47: 1229-1234 Year: 2016 Management of multidrug-resistant tuberculosis and patients in retreatment Source: Eur Respir J 2005; 25: 928-936 Year: 2005